Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Tolerability and safety of apomorphine SL (Ixense™)

International Journal of Impotence Research volume 15, pages S7–S9 (2003)Cite this article

Abstract

Apomorphine SL (Ixense™) (apo SL) is a dopamine receptor agonist that can enhance sexual function in patients with erectile dysfunction (ED). For a patient, the ability to achieve a physiological erection, tolerability, efficacy and the speed of onset of the therapy are of considerable importance when considering ED treatment. Recent studies have focused on determining the patient's tolerability to apo SL as a therapy for ED. In addition, the cardiovascular profile of those patients that would be likely to receive apo SL in the clinic has been assessed. These studies have shown that apo SL is safe and effective in the treatment of ED and offers a new therapeutic option for the first-line treatment of patients with different concomitant diseases including cardiovascular disease and diabetes. The most frequently reported adverse events were nausea and dizziness, but no major adverse events have been noted in any of the clinical trials.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Impotence. NIH Consens Statement Online, vol. 10, 7-12-1992, 1–31.

  2. Mulhall JP, Bukofzer S, Edmonds AL, George M . An open-label, uncontrolled dose-optimization study of sublingual apomorphine in erectile dysfunction. Clin Ther 2001; 23: 1260–1271.

    Article  CAS  Google Scholar 

  3. Von Keitz AT et al. A European multicentre study to evaluate the tolerability of apomorphine sublingual administered in a forced dose-escalation regimen in patients with erectile dysfunction. BJU Int 2002; 89: 409–415.

    Article  CAS  Google Scholar 

  4. Dula E, Bukofzer S, Perdok R, George M . Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur Urol 2001; 39: 558–564.

    Article  CAS  Google Scholar 

  5. Rosen RC et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822–830.

    Article  CAS  Google Scholar 

  6. Dula E et al. Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction. The Apomorphine Study Group. Urology 2000; 56: 130–135.

    Article  CAS  Google Scholar 

  7. Heaton JP . Apomorphine: an update of clinical trial results. Int J Impot Res 2000; 12(Suppl 4): S67–S73.

    Article  Google Scholar 

  8. Fagan TC, Buttler S, Marbury T, Taylor A, Edmonds A . Cardiovascular safety of sublingual apomorphine in patients on stable doses of oral antihypertensive agents and nitrates. Am J Cardiol 2001; 88: 760–766.

    Article  CAS  Google Scholar 

  9. Buvat J, Montorsi F . Safety and tolerability of apomorphine SL in patients with erectile dysfunction. BJU Int 2001; 88(Suppl 3): 30–35.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Universita' Vita e Salute San Raffaele, Milan, Italy

    F Montorsi

Authors
  1. F Montorsi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F Montorsi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Montorsi, F. Tolerability and safety of apomorphine SL (Ixense™). Int J Impot Res 15 (Suppl 2), S7–S9 (2003). https://doi.org/10.1038/sj.ijir.3900991

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3900991

Keywords

This article is cited by

Search

Advanced search

Quick links